key: cord-0729768-tn6y32zm authors: Avruscio, Giampiero; Camporese, Giuseppe; Campello, Elena; Bernardi, Enrico; Persona, Paolo; Passarella, Christian; Noventa, Franco; Cola, Marco; Navalesi, Paolo; Cattelan, Annamaria; Tiberio, Ivo; Boscolo, Annalisa; Spiezia, Luca; Simioni, Paolo title: COVID‐19 and venous thromboembolism in intensive care or medical ward date: 2020-09-29 journal: Clin Transl Sci DOI: 10.1111/cts.12907 sha: 8dd6e61ea088b7164b78d040b5d70398323df27d doc_id: 729768 cord_uid: tn6y32zm Despite thromboprophylaxis, patients with coronavirus‐19 disease (COVID‐19) exhibit hypercoagulability and higher venous thromboembolic risk, although its real incidence is still unknown. The aim of the study was to evaluate the incidence of venous thromboembolism in COVID‐19 patients admitted to both intensive care unit and medical ward. Consecutive patients admitted for COVID‐19 to medical ward and intensive care unit at Padua University Hospital, all receiving thromboprophylaxis, underwent systematic ultrasonography of internal jugular, upper and lower limbs veins every 7(±1) days after the admission; and if negative, once‐weekly until discharge or death. In case of suspected pulmonary embolism, a multi‐detector computed tomographic angiography was performed. The primary outcome was the proportion of any deep‐vein thrombosis and symptomatic pulmonary embolism in both groups. An extended blood coagulative test was performed as well. From March 4 to April 30, 2020 a total of 85 patients were investigated, 44 (52%) in medical ward and 41 (48%) in intensive care unit. Despite thromboprophylaxis, venous thromboembolism occurred in 12 medical ward (27.3%) and 31 intensive care unit patients (75.6%) with an Odds Ratio of 9.3 (95%CI, 3.5 to 24.5;p<0.001). Multiple‐site deep‐vein thrombosis occurred in 55.6% of patients (95%CI, 39.6 to 70.5). Increased D‐Dimer levels significantly correlated with venous thromboembolism (p=0.001) and death (p=0.015). Summarizing, COVID‐19 patients admitted to medical ward or intensive care unit showed a high frequency of venous thromboembolism, despite standard‐ or high‐dose thromboprophylaxis. Whether thrombosis, particularly asymptomatic events, may play a role in the morbidity and mortality of COVID‐19 patients remain to be clarified. The severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) has spread throughout the world starting from December 2019 and has not stopped yet, causing the occurrence of a new Coronavirus disease and becoming a global health threat. Most patients infected with SARS-CoV-2 are asymptomatic or experience a mild disease course. Nonetheless, about 14% of the COVID-19 patients are admitted to medical wards (MW), whereas about 5% develop a severe respiratory failure, thus requiring admission to intensive care units (ICU). 1 Venous thromboembolism (VTE) -including deep-vein thrombosis (DVT) and pulmonary embolism (PE) -is a common disease affecting 1-2/1000 persons per year in the general population, and most often arises as a complication of another pathological condition. 2 The VTE risk, in patients hospitalized in MW for an infectious respiratory disease, is as high as 5% and 17%, with and without thromboprophylaxis, respectively. The corresponding figures for patients admitted to ICU, are 16% and 31%, with and without thromboprophylaxis, respectively. [3] [4] [5] [6] [7] A number of specific factors, let alone respiratory failure per se, account for the higher VTE-prevalence observed in ICU patients, including central venous catheters, mechanical ventilation, and neuromuscular-blockade. [8] [9] [10] [11] Patients with COVID-19 may express coagulation activation at presentation, as shown by elevated D-dimer, which is associated with a worse clinical evolution and higher inhospital mortality. [12] [13] [14] [15] [16] [17] [18] Furthermore, COVID-19 patients who are admitted to an ICU may also experience a severe hypercoagulable state fostered by high serum levels of prothrombotic cytokines -which might place these patients at an even higher risk of developing VTE. 19, 20 In this sense, it is noteworthy that a number of recent studies, mostly retrospective, reported a similarly high incidence of VTE in patients with COVID-19 to that observed in patients hospitalized for a non-COVID infectious respiratory disease, being as high as 20%, and tending to be more frequent in patients admitted to the ICU than in those admitted to the MW. [21] [22] [23] [24] [25] [26] Based on these findings, we designed a prospective study, employing systematic ultrasonographic and laboratoristic screening to assess the actual incidence of VTE and hypercoagulable state in patients with COVID-19, admitted to the ICU or MW (Infectious This article is protected by copyright. All rights reserved Diseases Units) of Padua University Hospital. This was an observational cohort study. Our Institutional Review Board approved the study protocol, prior to data collection. Informed consent for non-invasive diagnostic procedures was managed according to internal hospital policy. The study was conducted in compliance with the principles of the Declaration of Helsinki. Consecutive patients aged ≥18 years with confirmed COVID-19 who were admitted to MW for a mild (slight clinical symptoms, no signs of pneumonia on imaging) to moderate (fever and respiratory symptoms, with pneumonia signs on imaging) disease; or to ICU for a severe [patients with any of the following conditions: respiratory distress with respiratory rate ≥ 30 breaths/min; SPO2 ≤ 93% at rest; PaO2/FiO2 ≤ 300mm Hg (1mm Hg = 0.133 kPa)] to critical (patients with any of the following conditions: respiratory failure requiring mechanical ventilation; shock; or other organ failure) disease, were enrolled. 27 COVID-19 was confirmed by a reverse transcription polymerase chain reaction on nasopharyngeal swabs or sputum samples. On admission, all patients were prescribed thromboprophylaxis with low-molecular-weight heparin (LMWH; enoxaparin 40 mg oncedaily) or fondaparinux (2.5 mg once-daily), according to current recommendations for medical patients. The primary outcome of the study was the incidence of symptomatic PE, as well as symptomatic or asymptomatic DVT in both groups. This article is protected by copyright. All rights reserved The secondary outcome was the incidence of superficial vein thrombosis (SVT) and hypercoagulable state in both groups. An independent committee, blinded on patients' allocation group, adjudicated the thromboembolic events based on all relevant documentation and footage. All patients underwent systematic bilateral color-coded Doppler ultrasonography (CCDU) Traditional coagulation parameters such as hemoglobin, platelet count, prothrombin time (PT)/international normalized ratio (INR), activated partial thromboplastin time (aPTT), fibrinogen, antithrombin, and D-dimer, as well as serum creatinine, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured in all enrolled patients. Whole blood thromboelastometry profiles were obtained using a ROTEM® Sigma apparatus (Instrumentation Laboratory -Werfen, Barcelona, Spain), as previously described. 19 INTEM and EXTEM assays (evaluation of intrinsic and extrinsic coagulation pathways) and FIBTEM test (evaluation of fibrinogen contribution to blood clot) were performed in all patients. The following ROTEM® parameters were analyzed: This article is protected by copyright. All rights reserved According to the literature, 5% and 15% of patients admitted to MW or ICU will experience VTE despite thromboprophylaxis. [3] [4] [5] [6] [7] Preliminary studies in COVID-19 patients report a remarkably high incidence of VTE, up to 3-fold that expected, despite thromboprophylaxis. [20] [21] [22] [23] [24] [25] Thus, we hypothesized that the incidence of VTE in our COVID-19 patients receiving thromboprophylaxis would be about 15% in patients admitted to MW, and about 45% in patients admitted to ICU, respectively. Based on these assumptions, we estimated that, including at least 42 subjects per group, the two-sided 95% confidence interval (CI) around the point estimate proportion for VTE would extend from 9·5% to 20·5%, and from 38% to 52%, in patients admitted to the MW and to ICU, respectively (nQuery Advisor v.5; Statistical Solutions, Cork, Ireland). Variables were first visually inspected, as usual: categorical variables with frequency tables, and continuous variables with sample statistics (e.g., average, median, standard deviation [SD], minimum and maximum value, 25 tth and 75 th quartile). The selected baseline covariates were then compared for 'like-to-like' in the two groups, with appropriate statistical tests for discrete and continuous variables. Primary and secondary outcomes analyses were performed on an intention-to-treat population, including all enrolled subjects. Raw cumulative proportions of subjects with VTE in the two groups were tested by Fisher's exact test. Cox's proportional hazard model was used to estimate hazard ratios for VTE occurrence, adjusted for various potential confounders, including group membership, age, gender, thromboprophylaxis dose, and all additional factors significantly associated with VTE at the univariate analysis (i.e.: obesity, chronic heart failure, hypertension, and several laboratory findings). Proportional hazards assumptions were first visually checked by log minus log survival plots for selected variables. Covariates significantly associated with the model were selected in a "forward stepwise" fashion, by the Wald method. This article is protected by copyright. All rights reserved The cumulative proportion of patients experiencing VTE was described by the Kaplan-Meier method, and differences were tested by the log-rank test. All statistical tests were 2-tailed, at a significance level of 0·05, unless otherwise specified. All analyses were performed with IBM-SPSS Statistics v.26 package (IBM-SPSS, Inc., Chicago, IL, USA). March 4 and April 30, 2020, 44 (52%) were admitted to the MW and 41 (48%) to the ICU. Baseline characteristics of the study population are summarized in Table 1 High doses were more often used in the ICU (41%), than in the MW (26%); to the contrary, standard doses were more frequently given in the MW (74%) than in the ICU (59%). There were no differences in terms of VTE between patients administered standard or high-dose prophylaxis (p=0.48), as reported in Table 2 . Standard or highdose prophylaxis did not account for different rates of VTE, when considering ICU and MW separately (Figures S1A-C) . Only one minor bleeding event was observed in an ICU patient on high-dose (60 mg once-daily) enoxaparin. This article is protected by copyright. All rights reserved Table 3 . Time-to-event analysis of VTE is shown in Figure 1 . Namely, the cumulative proportion of Overall, four patients (4.7%; 95%CI, 1.8 to 11.5) had PE. All PE events occurred in the ICU patients (9.8%; 95%CI, 3.9 to 22.5), and they were all fatal. (Table S1 ). This article is protected by copyright. All rights reserved Deep-vein thrombosis and SVT were symptomatic in 66% of the patients, without significant difference between the two groups. Catheter-related thrombosis occurred in 11 (13%) patients: two MW patients with peripherally inserted central venous-catheters (cephalic vein), and nine ICU patients with central venous catheters (common femoral or internal jugular veins). Of the many covariates evaluated with the Cox's proportional hazard model, only D-dimer plasma levels equal to or higher than 1000 ng/dL were significantly associated with VTE (hazard ratio, 2.2; 95%CI 1.1 to 4.4; p=0.034) ( Table S2 ). The cumulative proportion of VTE free patients by basal D-Dimer levels, overall and by setting, are reported in Figure S2A -C ICU patients developed more severe anemia (p=0.003) and significantly increased ALT (p=0.011) (Table S3) . No difference in creatinine levels was observed. All enrolled patients showed platelet count and coagulation times (PT/aPTT) within normal range, and elevated D-dimer levels -significantly higher in the ICU than in the MW (p=0.002). ICU patients also showed significantly increased fibrinogen levels (p=0.001), whereas antithrombin levels were similar and within normal range in both groups. As regards ROTEM parameters, the entire cohort showed higher MCF in FIBTEM (normal values 6-21 mm), indicating increased clot strength. ICU patients showed higher MCF in FIBTEM compared to MW (30.2 ± 7.6 mm vs. 35.6 ± 9.3 mm, p=0.066) ( Table S3 ). All patients who developed VTE showed significantly elevated D-dimer levels (p=0.001) and a trend towards MCF in FIBTEM increase (31.1 ± 9.9 mm vs. 35 ± 7.9 mm, p=0.19) (Table 4) . Notably, patients who died had significantly higher D-dimer levels (median 2196 ng/mL, 25/75 quartile, 1268-3233) than survivors (547 ng/mL, 25/75 quartile, 196-1624; p=0.015) This article is protected by copyright. All rights reserved The aim of the study was to prospectively investigate the incidence of VTE in consecutive patients with COVID-19-related pneumonia, admitted to the ICU or MW. Of note, all patients received either prophylactic-or high-dose LMWH or fondaparinux. We found an astounding 5-fold higher VTE incidence than that expected in similar patients without COVID-19 (Table 3 ). According to the literature, the prevalence of VTE in COVID-19 patients is increased up to 30%. 22-27 Indeed, previous studies 22-27 presented some diagnostic limitations, implying that the reported VTE incidence might have been underestimated. Noteworthy, we performed serial, once-week, CCDU throughout the whole hospitalization period in all patients, and this could explain the higher incidence of VTE recorded in our cohort. We also observed a significant 9-fold higher cumulative VTE risk in the ICU than in the MW (p=0.034) (Figure 1 ), that is again in agreement with published data, although on a different scale of magnitude. Pulmonary embolism was confirmed by CTPA or on clinical grounds in four of eight patients who died. This is in line with a recent autopsy study on COVID-19 patients, in which the prevalence of fatal PE was 33%; notably 58% also had asymptomatic DVT of the lower limbs or of the pelvic veins. 31 Interestingly, 56% of our patients had multiple-site DVT, an infrequent circumstance in similar COVID-19-free patients admitted to the ICU or the MW, that is an unique feature of our study. Such a frequent occurrence of multiple-site DVT fairly correlates with the hypercoagulable state observed in our patients, as inferred from the remarkably high D-Dimer and fibrinogen levels. Indeed, hypercoagulability appears to be a typical feature of COVID-19 patients. [12] [13] [14] [15] [16] [17] [18] [19] [20] Furthermore, we observed a significant direct correlation between high D-Dimer levels and both VTE (p=0.002) and mortality (p=0.015). Similarly, several recent retrospective studies, reported a strong direct correlation between D-dimer levels, VTE, and mortality, in COVID-19 patients. 15, 16, 20, 32 Overall 49% of the study patients, irrespective of both LMWH or fondaparinux doses prophylactic doses would be desirable, especially in order to also ascertain the risk of bleeding complications, particularly in the ICU patients. Of note, we registered only one minor bleeding episode in an ICU patient given high-dose LMWH. Our study presented some limitations. First, we included a small sample of patients, consequently the 95% CI around the point estimate of thromboembolic events is not acceptably narrow; however, even in the worst hypothesis, the estimated prevalence of VTE would be 16.3%, and 60.7%, in the MW and in the ICU, respectively; that is three-to four-fold the expected figure, in non-COVID-19 patients. Second, we do not have follow-up data on DVT-free patients who were discharged from the MW without thromboprophylaxis. However, according to the emergency department and the anagraphic databases of our Institution, there were no hospital readmissions or deaths of these patients, in the period from discharge up to May 15. This article is protected by copyright. All rights reserved Accepted Article Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Incidence and mortality of venous thrombosis: a population-based study Recent respiratory infection and risk of venous thromboembolism: case-control study through a general practice database Triggers for hospitalization for venous thromboembolism Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study Venous thromboembolism prophylaxis in critically ill patients Venous thromboembolism and its prevention in critical care Non-leg venous thrombosis in critically ill patients Venous thromboembolic disease: an observational study in medical-surgical intensive care unit patients Thromboprophylaxis in intensive care unit patients: a literature review VTE incidence and risk factors in patients with severe sepsis and septic shock Synergistic induction of tissue factor by coagulation factor Xa and TNF: evidence for involvement of negative regulatory signaling cascades The impact of the inflammatory response on coagulation Sustained high plasma plasminogen activator inhibitor-1 levels are associated with severity and mortalitty in septic patients D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19 D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis Clinical features of patients infected with novel 2019 coronavirus in Wuhan Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study COVID-19 -related severe hypercoagulability in patients admitted to Intensive Care Unit for acute respiratory failure The cytokine release The authors would like to dedicate their study to all the Italian patients, doctors, nurses, paramedics, and other volunteers who are fighting or lost their lives to COVID-19. G.C., E.C. and E.B wrote the manuscript. G.A., G.C., and E.C. designed the research. This article is protected by copyright. All rights reserved